Comparable stake leader
Lin Bioscience International Ltd.
SEC ownership of BELITE BIO, INC
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001889109.
Disclosed value leader
Lin Bioscience International Ltd.
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- BLTE on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Lin Bioscience International Ltd.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Lin Bioscience International Ltd.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001889109
- Issuer location
- San Diego, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of BELITE BIO, INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Lin Bioscience Internatio...
Disclosed value leader
Lin Bioscience Internatio...
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 54%
13D/G row: Lin Bioscience International Ltd.
Showing 1-8 of 50 holder rows.
Quick read
Lin Bioscience International Ltd. leads the comparable SEC ownership view at 54%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Lin Bioscience International Ltd.'s linked filing trail.
Comparable ownership
Top 5
Lin Bioscience International Ltd.
54%
Darwin Global Management, Ltd.
8.1%
Yu-Hsin Lin
3.1%
Paradigm Biocapital Advisors LP
2.8%
UBS Group AG
1.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Lin Bioscience International Ltd. |
13D/G
|
54%
|
$1,065,034,885
17,095,263 shares
|
$0 | 31 Dec 2024 |
| Darwin Global Management, Ltd. |
13D/G
13F
Company
|
8.1%
|
$479,467,205
3,027,704 shares
|
+$65,024,200 | 31 Dec 2025 |
| Yu-Hsin Lin |
13D/G
3/4/5
Chief Executive Officer, Director
|
3.1%
|
$212,905,624
1,253,935 shares
|
-$175,415,992 | 31 Mar 2026 |
| Paradigm Biocapital Advisors LP |
13F
Company
|
2.8%
|
$177,741,161
1,114,784 shares
|
— | 31 Mar 2026 |
| UBS Group AG |
13F
Company
|
1.9%
|
$122,507,159
768,359 shares
|
— | 31 Mar 2026 |
| RTW INVESTMENTS, LP |
13F
Company
|
1.8%
|
$114,052,534
715,332 shares
|
— | 31 Mar 2026 |
| MILLENNIUM MANAGEMENT LLC |
13F
Company
|
1.4%
|
$90,894,831
570,088 shares
|
— | 31 Mar 2026 |
| Holocene Advisors, LP |
13F
Company
|
1.2%
|
$78,842,283
494,495 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$8,524,794.
Buys
$0
Insiders: 0
Sells
$8,524,794
Insiders: 5
Net
-$8,524,794
Shares: -53,166
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 53,166
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 23,666 | $0 | $3,425,181 | -$3,425,181 |
| 3-6 | 0 | 29,500 | $0 | $5,099,613 | -$5,099,613 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-9 of 9 reporting-owner rows connected to BELITE BIO, INC. Open a relationship link for the CIK-to-CIK filing trail.
Rows
9
Largest Forms 3/4/5 holder
Yu-Hsin Lin
Net 12M change
-$8,524,794
Latest report
18 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Yu-Hsin Lin | Chief Executive Officer, Director | $60,450,859 | -$1,669,339 | -2.7% | Mixed | 21 Apr 2026 |
| Hao-Yuan Chuang | Chief Financial Officer, Director | $49,900,932 | -$1,125,303 | -2.2% | Mixed | 21 Apr 2026 |
| Hendrik Peter Scholl | Chief Medical Officer | $8,805,900 | -$2,858,165 | -25% | Mixed | 18 Jun 2026 |
| Wan-Shan Chen | Director | $6,065,140 | -$198,473 | -3.2% | Mixed | 09 Apr 2026 |
| Nathan L. Mata | Chief Scientific Officer | $3,142,374 | -$2,673,514 | -46% | Mixed | 07 May 2026 |
| Xiao-Hui Chen | Director | Mixed | 18 Mar 2026 | |||
| John Michael Longo | Director | Mixed | 18 Mar 2026 | |||
| Ita Lu | Director | Mixed | 18 Mar 2026 | |||
| Gary Clark Biddle | Director | Mixed | 18 Mar 2026 |
Recent insider transactions for BELITE BIO, INC
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Hendrik Peter Scholl | BLTE | American depositary share | Sale | -40% | $1,452,435 | $145.24 | -10,000 | 15,000 | 18 Jun 2026 | By Bioptima Ltd. |
| Hendrik Peter Scholl | BLTE | American depositary share | Sale | -28.6% | $1,405,729 | $140.57 | -10,000 | 25,000 | 16 Jun 2026 | By Bioptima Ltd. |
| Nathan L. Mata | BLTE | American depositary share | Sale | -100% | $102,039 | $153.21 | -666 | 0 | 07 May 2026 | Direct |
| Nathan L. Mata | BLTE | American depositary share | Sale | -60% | $153,839 | $153.84 | -1,000 | 666 | 06 May 2026 | Direct |
| Nathan L. Mata | BLTE | American depositary share | Sale | -37.5% | $155,502 | $155.50 | -1,000 | 1,666 | 05 May 2026 | Direct |
| Nathan L. Mata | BLTE | American depositary share | Sale | -27.3% | $155,636 | $155.64 | -1,000 | 2,666 | 04 May 2026 | Direct |
| Nathan L. Mata | BLTE | American depositary share | Sale | -21.4% | $155,778 | $155.78 | -1,000 | 3,666 | 01 May 2026 | Direct |
| Nathan L. Mata | BLTE | American depositary share | Sale | -17.6% | $156,973 | $156.97 | -1,000 | 4,666 | 30 Apr 2026 | Direct |
| Nathan L. Mata | BLTE | American depositary share | Sale | -15% | $155,817 | $155.82 | -1,000 | 5,666 | 29 Apr 2026 | Direct |
| Nathan L. Mata | BLTE | American depositary share | Sale | -13% | $159,162 | $159.16 | -1,000 | 6,666 | 28 Apr 2026 | Direct |
| Nathan L. Mata | BLTE | American depositary share | Sale | -11.5% | $162,641 | $162.64 | -1,000 | 7,666 | 27 Apr 2026 | Direct |
| Nathan L. Mata | BLTE | American depositary share | Sale | -10.4% | $159,556 | $159.56 | -1,000 | 8,666 | 24 Apr 2026 | Direct |
| Nathan L. Mata | BLTE | American depositary share | Sale | -9.38% | $166,284 | $166.28 | -1,000 | 9,666 | 23 Apr 2026 | Direct |
| Nathan L. Mata | BLTE | American depositary share | Sale | -8.57% | $170,384 | $170.38 | -1,000 | 10,666 | 22 Apr 2026 | Direct |
| Yu-Hsin Lin | BLTE | Ordinary Share | Other | 5.78% | 10,000 | 182,949 | 21 Apr 2026 | Direct | ||
| Hendrick Peter Scholl | BLTE | Stock Option (right to buy) | Other | 10,000 | 10,000 | 21 Apr 2026 | By Bioptima Ltd. | |||
| Hao-Yuan Chuang | BLTE | Ordinary Share | Other | 5.12% | 10,000 | 205,264 | 21 Apr 2026 | Direct | ||
| Nathan L. Mata | BLTE | American depositary share | Sale | -7.9% | $166,000 | $166.00 | -1,000 | 11,666 | 21 Apr 2026 | Direct |
| Nathan L. Mata | BLTE | American depositary share | Sale | -7.32% | $163,595 | $163.59 | -1,000 | 12,666 | 20 Apr 2026 | Direct |
| Nathan L. Mata | BLTE | American depositary share | Sale | -6.82% | $161,630 | $161.63 | -1,000 | 13,666 | 17 Apr 2026 | Direct |
| Nathan L. Mata | BLTE | American depositary share | Sale | -6.38% | $160,381 | $160.38 | -1,000 | 14,666 | 16 Apr 2026 | Direct |
| Nathan L. Mata | BLTE | American depositary share | Sale | -6% | $168,298 | $168.30 | -1,000 | 15,666 | 15 Apr 2026 | Direct |
| Yu-Hsin Lin | BLTE | American depositary share | Sale | -5.11% | $1,669,339 | $181.45 | -9,200 | 170,934 | 09 Apr 2026 | Direct |
| Wan-Shan Chen | BLTE | American depositary share | Sale | -10.8% | $198,473 | $180.43 | -1,100 | 9,096 | 09 Apr 2026 | Direct |
| Hao-Yuan Chuang | BLTE | American depositary share | Sale | -6.2% | $1,125,303 | $181.50 | -6,200 | 93,800 | 09 Apr 2026 | Direct |
| Wan-Shan Chen | BLTE | Stock Option (right to buy) | Award | 13,796 | 13,796 | 31 Mar 2026 | Direct | |||
| Hao-Yuan Chuang | BLTE | Stock Option (right to buy) | Award | 100% | 144,868 | 289,736 | 31 Mar 2026 | Direct | ||
| Nathan L. Mata | BLTE | Stock Option (right to buy) | Award | 117.7% | 144,868 | 267,934 | 31 Mar 2026 | Direct | ||
| Yu-Hsin Lin | BLTE | Stock Option (right to buy) | Award | 100% | 206,954 | 413,908 | 31 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.